PUBLISHER: IMARC | PRODUCT CODE: 1422943
PUBLISHER: IMARC | PRODUCT CODE: 1422943
MRSA Drugs Market by MRSA Type (Hospital-Acquired, Community-Acquired ), Drug Class, Disease Indication, Route of Administration, Distribution Channel, and Region 2024-2032
Abstract
The global MRSA drugs market size reached US$ 3.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.0 Billion by 2032, exhibiting a growth rate (CAGR) of 3.11% during 2024-2032. The rising prevalence of antibiotic resistant strains development, continual exposure to multidrug-resistant organisms in healthcare facilities due to prolonged hospital admission and the growing number of clinical trials represent some of the key factors driving the market.
Methicillin-resistant staphylococcus aureus (MRSA) is an infection caused by antibiotic-resistant strains of staphylococcus aureus that generally occurs in patients who undergo surgical procedures, receive intravenous tubing, or come in contact with each other skin-to-skin. The MRSA drugs are used as antimicrobial agents against methicillin-resistant staphylococcus aureus infection in order to kill or restrain it. They inhibit the actions of pathogens while enhancing the patient's cellular synthesis and immunity. The most common MRSA drugs consist of trimethoprim-sulfamethoxazole, clindamycin, minocycline, linezolid, or doxycycline. These drugs are generally used as oral medication, usually on a course of seven to ten days. MRSA infections can arise from hospitals or from community, hence the treatment for MRSA can sometimes involve the administration of oral medications and intravenous (IV) medications, depending on the severity. There are a wide variety of MRSA drugs available that can be used for the treatment of different types of infections, including skin infections, bone infections, bacteremia, and even zoonotic infections in animals.
MRSA Drugs Market Trends:
The rising prevalence of antibiotic resistant strains development among the masses is a significant factor driving the growth of the market. This can be attributed to the increase in the number of cases of hospital-acquired infections (HAIs) on the global level. Also, the continual exposure to multidrug-resistant organisms in healthcare facilities due to prolonged hospital admission is resulting in the development of secondary nosocomial infections, thereby propelling the market. In addition to this, the growing geriatric population that is more susceptible to developing MRSA infections is providing an impetus to the market. Moreover, the augmenting awareness regarding different forms of bacterial infection is leading to a higher uptake of MRSA drugs. In line with this, numerous product innovations, growing number of clinical trials and the introduction of novel drug variants are creating lucrative growth opportunities in the market. However, the high costs involved in developing novel MRSA drug variants is acting as major growth restraining-factor for the market. On the contrary, continual technological developments in various diagnostic tools, along with the increasing number of clinical trial programs for the screening of antibiotic resistant strains of bacteria, are creating a positive market outlook. The market is further impelled by extensive research and development (R&D) activities conducted by the key players. Some of the other factors contributing to the market include the emergence of generic drugs against presently available products, easy availability of antibiotics across online and offline organized platforms, rapid urbanization, and increasing medical expenditure.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global MRSA drugs market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on MRSA type, drug class, disease indication, route of administration, and distribution channel.
MRSA Type Insights
Hospital-Acquired (HA-MRSA)
Community-Acquired (CA-MRSA)
The report has provided a detailed breakup and analysis of the MRSA drugs market based on the MRSA type. This includes Hospital-Acquired (HA-MRSA) and Community-Acquired (CA-MRSA). According to the report, Hospital-Acquired (HA-MRSA) represented the largest segment.
Drug Class Insights
Lipopeptides
Oxazolidinones
Cephalosporin
Tetracycline
Folate Antagonist
Others
The report has provided a detailed breakup and analysis of the MRSA drugs market based on the drug class. This includes lipopeptides, oxazolidinones, cephalosporin, tetracycline, folate antagonist, and others. According to the report, lipopeptides represented the largest segment.
Disease Indication Insights
Skin Infections
Bone and Joint Infections
Bacteremia
Animal Infections
The report has provided a detailed breakup and analysis of the MRSA drugs market based on the disease indication. This includes skin infections, bone and joint infections, bacteremia, and animal infections. According to the report, skin Infections represented the largest segment.
Route of Administration Insights
Oral Administration
Parenteral Administration
The report has provided a detailed breakup and analysis of the MRSA drugs market based on the route of administration. This includes oral administration and parenteral administration. According to the report, parenteral administration represented the largest segment.
Distribution Channel Insights
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
A detailed breakup and analysis of the MRSA drugs market based on the distribution channel has also been provided in the report. This includes hospital pharmacies, retail pharmacies, and online pharmacies. According to the report, hospital pharmacies accounted for the largest market share.
Regional Insights:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for MRSA drugs. Some of the factors driving the North America MRSA drugs market include the rising medical expenditure, the increasing number of clinical trial programs, extensive research and development (R&D) activities conducted by key players, etc.
Competitive Landscape
The report has also provided a comprehensive analysis of the competitive landscape in the global MRSA drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include AbbVie Inc., Basilea Pharmaceutica Ltd, Crystal Genomics Inc., Cumberland Pharmaceuticals Inc., Melinta Therapeutics Inc, Paratek Pharmaceuticals, Inc., Pfizer Inc, etc.
Key Questions Answered in This Report:
- How has the global MRSA drugs market performed so far and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global MRSA drugs market?
- What are the key regional markets?
- Which countries represent the most attractive MRSA drugs markets?
- What is the breakup of the market based on the MRSA type?
- What is the breakup of the market based on the drug class?
- What is the breakup of the market based on the disease indication?
- What is the breakup of the market based on the route of administration?
- What is the breakup of the market based on the distribution channel?
- What is the competitive structure of the global MRSA drugs market?
- Who are the key players/companies in the global MRSA drugs market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global MRSA Drugs Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by MRSA Type
- 6.1 Hospital-Acquired (HA-MRSA)
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Community-Acquired (CA-MRSA)
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Drug Class
- 7.1 Lipopeptides
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Oxazolidinones
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Cephalosporin
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Tetracycline
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Folate Antagonist
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
- 7.6 Others
- 7.6.1 Market Trends
- 7.6.2 Market Forecast
8 Market Breakup by Disease Indication
- 8.1 Skin Infections
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Bone and Joint Infections
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Bacteremia
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Animal Infections
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
9 Market Breakup by Route of Administration
- 9.1 Oral Administration
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Parenteral Administration
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
10 Market Breakup by Distribution Channel
- 10.1 Hospital Pharmacies
- 10.1.1 Market Trends
- 10.1.2 Market Forecast
- 10.2 Retail Pharmacies
- 10.2.1 Market Trends
- 10.2.2 Market Forecast
- 10.3 Online Pharmacies
- 10.3.1 Market Trends
- 10.3.2 Market Forecast
11 Market Breakup by Region
- 11.1 North America
- 11.1.1 United States
- 11.1.1.1 Market Trends
- 11.1.1.2 Market Forecast
- 11.1.2 Canada
- 11.1.2.1 Market Trends
- 11.1.2.2 Market Forecast
- 11.1.1 United States
- 11.2 Asia-Pacific
- 11.2.1 China
- 11.2.1.1 Market Trends
- 11.2.1.2 Market Forecast
- 11.2.2 Japan
- 11.2.2.1 Market Trends
- 11.2.2.2 Market Forecast
- 11.2.3 India
- 11.2.3.1 Market Trends
- 11.2.3.2 Market Forecast
- 11.2.4 South Korea
- 11.2.4.1 Market Trends
- 11.2.4.2 Market Forecast
- 11.2.5 Australia
- 11.2.5.1 Market Trends
- 11.2.5.2 Market Forecast
- 11.2.6 Indonesia
- 11.2.6.1 Market Trends
- 11.2.6.2 Market Forecast
- 11.2.7 Others
- 11.2.7.1 Market Trends
- 11.2.7.2 Market Forecast
- 11.2.1 China
- 11.3 Europe
- 11.3.1 Germany
- 11.3.1.1 Market Trends
- 11.3.1.2 Market Forecast
- 11.3.2 France
- 11.3.2.1 Market Trends
- 11.3.2.2 Market Forecast
- 11.3.3 United Kingdom
- 11.3.3.1 Market Trends
- 11.3.3.2 Market Forecast
- 11.3.4 Italy
- 11.3.4.1 Market Trends
- 11.3.4.2 Market Forecast
- 11.3.5 Spain
- 11.3.5.1 Market Trends
- 11.3.5.2 Market Forecast
- 11.3.6 Russia
- 11.3.6.1 Market Trends
- 11.3.6.2 Market Forecast
- 11.3.7 Others
- 11.3.7.1 Market Trends
- 11.3.7.2 Market Forecast
- 11.3.1 Germany
- 11.4 Latin America
- 11.4.1 Brazil
- 11.4.1.1 Market Trends
- 11.4.1.2 Market Forecast
- 11.4.2 Mexico
- 11.4.2.1 Market Trends
- 11.4.2.2 Market Forecast
- 11.4.3 Others
- 11.4.3.1 Market Trends
- 11.4.3.2 Market Forecast
- 11.4.1 Brazil
- 11.5 Middle East and Africa
- 11.5.1 Market Trends
- 11.5.2 Market Breakup by Country
- 11.5.3 Market Forecast
12 Drivers, Restraints, and Opportunities
- 12.1 Overview
- 12.2 Drivers
- 12.3 Restraints
- 12.4 Opportunities
13 Value Chain Analysis
14 Porters Five Forces Analysis
- 14.1 Overview
- 14.2 Bargaining Power of Buyers
- 14.3 Bargaining Power of Suppliers
- 14.4 Degree of Competition
- 14.5 Threat of New Entrants
- 14.6 Threat of Substitutes
15 Price Analysis
16 Competitive Landscape
- 16.1 Market Structure
- 16.2 Key Players
- 16.3 Profiles of Key Players
- 16.3.1 AbbVie Inc.
- 16.3.1.1 Company Overview
- 16.3.1.2 Product Portfolio
- 16.3.1.3 Financials
- 16.3.1.4 SWOT Analysis
- 16.3.2 Basilea Pharmaceutica Ltd
- 16.3.2.1 Company Overview
- 16.3.2.2 Product Portfolio
- 16.3.3 Crystal Genomics Inc.
- 16.3.3.1 Company Overview
- 16.3.3.2 Product Portfolio
- 16.3.3.3 Financials
- 16.3.4 Cumberland Pharmaceuticals Inc
- 16.3.4.1 Company Overview
- 16.3.4.2 Product Portfolio
- 16.3.4.3 Financials
- 16.3.5 Melinta Therapeutics Inc
- 16.3.5.1 Company Overview
- 16.3.5.2 Product Portfolio
- 16.3.5.3 Financials
- 16.3.6 Paratek Pharmaceuticals, Inc.
- 16.3.6.1 Company Overview
- 16.3.6.2 Product Portfolio
- 16.3.6.3 Financials
- 16.3.6.4 SWOT Analysis
- 16.3.7 Pfizer Inc
- 16.3.7.1 Company Overview
- 16.3.7.2 Product Portfolio
- 16.3.7.3 Financials
- 16.3.7.4 SWOT Analysis
- 16.3.1 AbbVie Inc.
List of Figures
- Figure 1: Global: MRSA Drugs Market: Major Drivers and Challenges
- Figure 2: Global: MRSA Drugs Market: Sales Value (in Billion US$), 2018-2023
- Figure 3: Global: MRSA Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
- Figure 4: Global: MRSA Drugs Market: Breakup by MRSA Type (in %), 2023
- Figure 5: Global: MRSA Drugs Market: Breakup by Drug Class (in %), 2023
- Figure 6: Global: MRSA Drugs Market: Breakup by Disease Indication (in %), 2023
- Figure 7: Global: MRSA Drugs Market: Breakup by Route of Administration (in %), 2023
- Figure 8: Global: MRSA Drugs Market: Breakup by Distribution Channel (in %), 2023
- Figure 9: Global: MRSA Drugs Market: Breakup by Region (in %), 2023
- Figure 10: Global: MRSA Drugs (Hospital-Acquired (HA-MRSA)) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 11: Global: MRSA Drugs (Hospital-Acquired (HA-MRSA)) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 12: Global: MRSA Drugs (Community-Acquired (CA-MRSA)) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 13: Global: MRSA Drugs (Community-Acquired (CA-MRSA)) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 14: Global: MRSA Drugs (Lipopeptides) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 15: Global: MRSA Drugs (Lipopeptides) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 16: Global: MRSA Drugs (Oxazolidinones) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 17: Global: MRSA Drugs (Oxazolidinones) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 18: Global: MRSA Drugs (Cephalosporin) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 19: Global: MRSA Drugs (Cephalosporin) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 20: Global: MRSA Drugs (Tetracycline) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 21: Global: MRSA Drugs (Tetracycline) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 22: Global: MRSA Drugs (Folate Antagonist) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 23: Global: MRSA Drugs (Folate Antagonist) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 24: Global: MRSA Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 25: Global: MRSA Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 26: Global: MRSA Drugs (Skin Infections) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 27: Global: MRSA Drugs (Skin Infections) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 28: Global: MRSA Drugs (Bone and Joint Infections) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 29: Global: MRSA Drugs (Bone and Joint Infections) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 30: Global: MRSA Drugs (Bacteremia) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 31: Global: MRSA Drugs (Bacteremia) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 32: Global: MRSA Drugs (Animal Infections) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 33: Global: MRSA Drugs (Animal Infections) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 34: Global: MRSA Drugs (Oral Administration) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 35: Global: MRSA Drugs (Oral Administration) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 36: Global: MRSA Drugs (Parenteral Administration) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 37: Global: MRSA Drugs (Parenteral Administration) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 38: Global: MRSA Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 39: Global: MRSA Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 40: Global: MRSA Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 41: Global: MRSA Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 42: Global: MRSA Drugs (Online Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 43: Global: MRSA Drugs (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 44: North America: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 45: North America: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 46: United States: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 47: United States: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 48: Canada: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 49: Canada: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 50: Asia-Pacific: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 51: Asia-Pacific: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 52: China: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 53: China: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 54: Japan: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 55: Japan: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 56: India: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 57: India: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 58: South Korea: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 59: South Korea: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 60: Australia: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 61: Australia: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 62: Indonesia: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 63: Indonesia: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 64: Others: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 65: Others: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 66: Europe: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 67: Europe: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 68: Germany: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 69: Germany: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 70: France: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 71: France: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 72: United Kingdom: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 73: United Kingdom: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 74: Italy: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 75: Italy: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 76: Spain: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 77: Spain: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 78: Russia: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 79: Russia: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 80: Others: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 81: Others: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 82: Latin America: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 83: Latin America: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 84: Brazil: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 85: Brazil: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 86: Mexico: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 87: Mexico: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 88: Others: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 89: Others: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 90: Middle East and Africa: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 91: Middle East and Africa: MRSA Drugs Market: Breakup by Country (in %), 2023
- Figure 92: Middle East and Africa: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 93: Global: MRSA Drugs Industry: Drivers, Restraints, and Opportunities
- Figure 94: Global: MRSA Drugs Industry: Value Chain Analysis
- Figure 95: Global: MRSA Drugs Industry: Porter's Five Forces Analysis
List of Tables
- Table 1: Global: MRSA Drugs Market: Key Industry Highlights, 2023 & 2032
- Table 2: Global: MRSA Drugs Market Forecast: Breakup by MRSA Type (in Million US$), 2024-2032
- Table 3: Global: MRSA Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
- Table 4: Global: MRSA Drugs Market Forecast: Breakup by Disease Indication (in Million US$), 2024-2032
- Table 5: Global: MRSA Drugs Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
- Table 6: Global: MRSA Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
- Table 7: Global: MRSA Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
- Table 8: Global: MRSA Drugs Market: Competitive Structure
- Table 9: Global: MRSA Drugs Market: Key Players
